Novel Modulators of α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) Identified – March 2016

TES Pharma annouces the publication of a US patent application US2016006022(A1) covering the first series of novel inhibitors of α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) a key enzyme in the NAD+ biosynthetic pathway.

As inhibitors of ACMSD these compounds are useful for the prevention and/or treatment of diseases and disorders associated with defects in NAD+ biosynthesis, e.g. metabolic disorders, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing.